Pfizer and BioNTech have reported first results from a pivotal trial of a COVID-19 vaccine in children 5-11 years.
The results show a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age using a two-dose regimen of 10 µg administered 21 days apart, a smaller dose than the 30 µg dose used for people 12 and older.